Ranbaxy announced its launch of Pioglitazone HCl tablets, the generic version of Takeda‘s Actos.

Pioglitazone HCl is an oral antidiabetic agent that acts primarily by decreasing insulin resistance, It is indicated for patients as an adjunct to diet and exercise to improve glycemic controls in adults with type 2 diabetes mellitus, and as monotherapy or in combination with metformin, insulin, or a sulfonylurea. 

Ranbaxy’s Pioglitazone HCl tablets will be available in 15mg, 30mg, and 45mg dosage strengths.

For more information call (609) 720-9200 or visit www.ranbaxy.com.